6.26
전일 마감가:
$5.90
열려 있는:
$5.93
하루 거래량:
1.44M
Relative Volume:
1.19
시가총액:
$177.86M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
-5.3966
EPS:
-1.16
순현금흐름:
$-21.00M
1주 성능:
-13.89%
1개월 성능:
-72.97%
6개월 성능:
-48.48%
1년 성능:
-63.33%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
ARCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ARCT
Arcturus Therapeutics Holdings Inc
|
6.26 | 167.63M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Responsive Playbooks and the ARCT Inflection - news.stocktradersdaily.com
What drives Arcturus Therapeutics Holdings Inc stock priceLow Beta Stocks & Free Trend Following Techniques - earlytimes.in
Arcturus Therapeutics Hits 52-Week Low at $5.85 Amid Financial Struggles - Markets Mojo
Is Arcturus Therapeutics Holdings Inc. stock a safe haven assetJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Balyasny Asset Management L.P. Increases Stake in Arcturus Thera - GuruFocus
Arcturus Therapeutics Hits 52-Week Low at $6.02 Amid Major Decline - Markets Mojo
Is Arcturus Therapeutics Holdings Inc. stock ready for a breakoutJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
What candlestick patterns are forming on Arcturus Therapeutics Holdings Inc. - newser.com
Can Arcturus Therapeutics Holdings Inc. stock beat market expectations this quarterJuly 2025 Analyst Calls & Fast Entry High Yield Tips - newser.com
Can momentum traders help lift Arcturus Therapeutics Holdings Inc.2025 Performance Recap & Detailed Earnings Play Strategies - newser.com
How Arcturus Therapeutics Holdings Inc. stock responds to policy changesNew Guidance & AI Powered Market Trend Analysis - newser.com
Arcturus Therapeutics Hits 52-Week Low at $6.72 Amid Ongoing Struggles - Markets Mojo
Arcturus Therapeutics Hits 52-Week Low at $7.26 Amid Financial Struggles - Markets Mojo
Arcturus Therapeutics Holdings (ARCT) Price Target Decreased by 28.26% to 32.77 - MSN
How to forecast Arcturus Therapeutics Holdings Inc. trends using time series2025 Price Momentum & Verified Trade Idea Suggestions - newser.com
How currency fluctuations impact Arcturus Therapeutics Holdings Inc. stockJuly 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to “Hold” - Defense World
Published on: 2025-11-15 17:06:19 - newser.com
What technical models suggest about Arcturus Therapeutics Holdings Inc.’s comeback2025 Market Outlook & Momentum Based Trading Signals - newser.com
Arcturus Therapeutics Holdings Inc. stock volume spike explained2025 EndofYear Setup & High Accuracy Trade Alerts - newser.com
Arcturus Therapeutics Hits New 52-Week Low at $7.76 - Markets Mojo
What is William Blair’s Forecast for ARCT FY2025 Earnings? - Defense World
How to use a screener to detect Arcturus Therapeutics Holdings Inc. breakoutsJuly 2025 Recap & Precise Swing Trade Alerts - newser.com
Citigroup Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - Nasdaq
Arcturus outlines 12-week cystic fibrosis study launch in 2026 amid cost controls and delayed KOSTAIVE BLA - MSN
ARCT: Citigroup Adjusts Price Target and Maintains Neutral Ratin - GuruFocus
Arcturus cut to Neutral at Citi on data for mRNA candidate - MSN
Is Arcturus Therapeutics Holdings Inc. stock cheap at current valuation2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
What MACD signals say about Arcturus Therapeutics Holdings Inc.Rate Hike & AI Powered Buy and Sell Recommendations - newser.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2025 Earnings Call Transcript - Insider Monkey
Arcturus Therapeutics Holdings Inc. SEC 10-Q Report - TradingView
[10-Q] Arcturus Therapeutics Holdings Inc. Quarterly Earnings Report | ARCT SEC FilingForm 10-Q - Stock Titan
ARCT: HC Wainwright & Co. Lowers Price Target, Maintains Neutral Rating | ARCT Stock News - GuruFocus
Understanding the Setup: (ARCT) and Scalable Risk - news.stocktradersdaily.com
Piper Sandler Maintains Arcturus Therapeutics Holdings (ARCT) Overweight Recommendation - Nasdaq
Arcturus Therapeutics (ARCT) Target Price Significantly Lowered by Piper Sandler | ARCT Stock News - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):